All In Biotech

Drug Trial Radar · NCT04565015

Study of Immune Globulin Intravenous (Human) GC5107 in Pediatric Subjects With Primary Humoral Immunodeficiency

An Open-Label, Single-Arm, Historically Controlled, Prospective, Multi-Center Phase III Study to Evaluate the Pharmacokinetics and Safety of Immune Globulin Intravenous (Human) GC5107 in Pediatric Subjects With Primary Humoral Immunodeficiency

Last checked: Nov 19, 2026Latest source record: Jul 25, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

24

Planned (sponsor's estimate)

Start

Dec 21, 2020

Primary completion

May 2026

Study completion Nov 2026

Sponsor

Lead sponsor
GC Biopharma CorpIndustry
Sponsor type
Industry
Collaborators
Atlantic Research Group
First posted
Sep 25, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 2 years, up to 16 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the pharmacokinetics and safety of Immune Globulin Intravenous (Human) GC5107 in pediatric subjects with Primary Humoral Immunodeficiency (PHID).

Conditions

  • Primary Immune Deficiency

Interventions

  • GC5107Biological

    Intravenously infused at a dose of 300 - 900 mg per kg (of body weight) every 21 or 28 days for 12 months

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The Pharmacokinetic (PK) Plasma concentration-time curve of total IgGTime frame: before and after 5th infusion (12 or 16 weeks)
  2. The Pharmacokinetic (PK) Half-life of total IgGTime frame: before and after 5th infusion (12 or 16 weeks)
  3. The Pharmacokinetic (PK) Area under the curve of total IgGTime frame: before and after 5th infusion (12 or 16 weeks)
  4. The Pharmacokinetic (PK) Volume of distribution of total IgGTime frame: before and after 5th infusion (12 or 16 weeks)
  5. The Pharmacokinetic (PK) Maximum concentration of total IgGTime frame: before and after 5th infusion (12 or 16 weeks)
  6. The Pharmacokinetic (PK) Minimum concentration of total IgGTime frame: before and after 5th infusion (12 or 16 weeks)
  7. The Pharmacokinetic (PK) Time of maximum concentration of total IgGTime frame: before and after 5th infusion (12 or 16 weeks)
  8. The Pharmacokinetic (PK) Clearance of total IgGTime frame: before and after 5th infusion (12 or 16 weeks)
  9. Trough serum total IgG levels before each infusion of GC5107 in all subjects and the interval between infusionsTime frame: 12 months
  10. The proportion of infusions with temporally associated adverse events (AEs) that occur during or within 1 hour, 24 hours, and 72 hours following an infusion of investigational productTime frame: 12 months

Locations

8 sites in 3 countries. Site status is shown where the registry gives one.

  • Children's Hospital Colorado

    Aurora, Colorado

  • Immunoe Health & Research Centers

    Centennial, Colorado

  • Allergy Partners of North Texas Research

    Dallas, Texas

  • Lysosomal and Rare Disorders Research and Treatment Center, Inc.

    Fairfax, Virginia

  • Children's Hospital of Richmond at VCU

    Richmond, Virginia

  • University Clinical Center Sarajevo

    Sarajevo, Sarajevo, Bosnia and Herzegovina

  • University clinical center Tuzla

    Tuzla, Tuzla, Bosnia and Herzegovina

  • Institute for Child and Youth Health Care of Vojvodina

    Novi Sad, Novi Sad, Serbia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.